Pull to refresh
Logo
Marvell agrees to buy Lumentum in all-stock AI optics deal

Marvell agrees to buy Lumentum in all-stock AI optics deal

Money Moves

The $115 billion transaction would put the signal chip and the laser of an AI network's optical link under one roof

Overview

Updated 1 hour ago

Marvell Technology agreed on November 2, 2026 to buy Lumentum for about $115 billion in stock. Lumentum shareholders get 4.5 Marvell shares for each share they own, leaving them with roughly a third of the combined company.

The deal pairs the chips that drive signals through an AI data center with the lasers that carry those signals. Marvell is betting optical links, not copper wire, become the standard way to connect clusters of AI accelerators as models grow.

Why it matters

If it closes, one company will sell both the processor and the laser at each optical link in an AI cluster.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$115B
Implied enterprise value
Equity value is about $102.6 billion; the rest is assumed net debt.
23.9%
Premium to unaffected price
Measured against Lumentum's October 28, 2026 close, before deal speculation surfaced.
4.5 : 1
Fixed exchange ratio
Marvell shares issued per Lumentum share; the value moves with Marvell's stock price.
67% / 33%
Ownership split after closing
Marvell holders keep 67% of the combined company on a fully diluted basis; Lumentum holders take 33%.
$1B+
Annual cost savings targeted
Management's estimated run-rate synergies once the companies are integrated.
-12.7%
Marvell shares on the announcement
Lumentum fell 18.6% the same session, cutting the value of the all-stock offer.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2026 November 2026

5 events Latest: Today
Tap a bar to jump to that date
  1. Bank of America downgrades Marvell

    Today Analyst reaction

    Cut to neutral from buy, price target $225 from $400, citing China review and dilution.

  2. Marvell agrees to buy Lumentum

    Deal

    All-stock deal at 4.5 Marvell shares per Lumentum share, $115 billion enterprise value.

  3. Unaffected closing prices set the baseline

    Market

    Last trading day before speculation; the 23.9% premium is measured from here.

  4. Merger talks reported

    Market

    After talks surface, Lumentum falls about 8% and Marvell about 22%.

  5. Nvidia takes stakes in both companies

    Investment

    Nvidia invests $2 billion each in Marvell and Lumentum.

Scenarios

1

Deal closes in 2028 as signed

Likely Resolves by Q2 2028

Discussed by: Marvell and Lumentum management, in the merger announcement

Both shareholder votes pass, US and European reviews clear, and Chinese regulators allow the deal through in time for the first half of 2028 outside date. Marvell absorbs Lumentum's laser fabs and transceiver line and sells a combined optical engine. The $1 billion in annual cost cuts arrive on the schedule management has described.

2

China review stretches past the outside date

Possible Resolves by End of 2028

Discussed by: Bank of America analyst Vivek Arya, in a November 2 note

Arya named the extended regulatory process, China included, as his first concern about the deal. A prolonged review would leave both companies in limbo for more than a year, with Lumentum unable to take on conflicting customers and Marvell carrying the overhang.

3

Shareholders or a rival bidder change the terms

Unlikely Resolves by End of 2027

Discussed by: Not yet a consensus view; the all-stock structure and falling Marvell price make it a live question

Because the exchange ratio is fixed, every drop in Marvell's share price cuts what Lumentum holders receive. A large enough decline could push Lumentum directors to reopen terms, or invite a competing offer. Marvell shareholders could also vote down the share issuance needed to fund the deal.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

October 2020 – February 2022

AMD buys Xilinx (2020–2022)

AMD agreed to buy Xilinx in an all-stock deal worth roughly $49 billion, one of the largest chip mergers ever attempted. The transaction needed approval from regulators in the US, Europe and China, and China's sign-off arrived only near the end of the 18-month process.

Then

The deal closed in February 2022 after China's regulator granted conditional approval.

Now

It established that large all-stock semiconductor mergers can clear Beijing, but only slowly and with conditions attached.

Why this matters now

The Marvell-Lumentum deal follows the same shape: fixed exchange ratio, long regulatory calendar, and China as the decisive last approval.

May 2022 – November 2023

Broadcom buys VMware (2022–2023)

Broadcom agreed to buy software maker VMware for about $69 billion, then spent 18 months clearing reviews in the US, Europe, the UK and China. Regulators demanded behavioral commitments on pricing and interoperability before allowing it through.

Then

The deal closed in November 2023 after Broadcom made concessions to multiple agencies.

Now

It set the template for how long a deal of this size takes and how much remedy negotiating it requires.

Why this matters now

Marvell has targeted the first half of 2028 for closing, a timeline that assumes a review as long as Broadcom's.

September 2020 – February 2022

Nvidia's bid for Arm (2020–2022)

Nvidia agreed to buy chip designer Arm for about $40 billion. Regulators in the US, UK and Europe challenged the deal on competition grounds, and Arm's owner SoftBank eventually moved to sell shares to the public instead.

Then

The acquisition was abandoned in February 2022.

Now

It became the clearest example of a semiconductor merger failing outright on antitrust grounds.

Why this matters now

It is the downside case for Marvell: a large, strategically motivated chip acquisition that regulators can simply refuse.

Sources

(8)